Thomas Ross - Bausch Health Lead Independent Director
| BHC Stock | USD 7.95 0.02 0.25% |
Director
Mr. Thomas W. Ross, Sr. is Lead Independent Director of the Company. He has served on the Board since March 2016 and was appointed our Lead Independent Director in June 2016. He has served as the President of Volcker Alliance since July 2016, where he also serves as a director. He is President Emeritus of the University of North Carolina, having served as President from January 2011 to January 2016. Mr. Ross currently serves as the Sanford Distinguished Fellow in Public Policy at the Duke University Sanford School of Public Policy. Prior to becoming President of the UNC system, Mr. Ross served as President of Davidson College, Executive Director of the Z. Smith Reynolds Foundation, director of the North Carolina Administrative Office of the Courts, a Superior Court judge, chief of staff to U.S. Congressman Robin Britt, a member of the Greensboro, NC law firm Smith, Patterson, Follin, Curtis, James Harkavy, and as an Assistant Professor of Public Law and Government at UNC Chapel Hills School of Government. since 2016.
| Age | 69 |
| Tenure | 8 years |
| Address | 2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8 |
| Phone | 514 744 6792 |
| Web | https://www.bauschhealth.com |
Thomas Ross Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas Ross against Bausch Health stock is an integral part of due diligence when investing in Bausch Health. Thomas Ross insider activity provides valuable insight into whether Bausch Health is net buyers or sellers over its current business cycle. Note, Bausch Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bausch Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas Ross over three months ago Disposition of 17857 shares by Thomas Ross of MaxCyte at 1.641 subject to Rule 16b-3 | ||
Thomas Ross over three months ago Disposition of 19802 shares by Thomas Ross of MaxCyte at 4.029 subject to Rule 16b-3 | ||
Thomas Ross over three months ago Disposition of 33333 shares by Thomas Ross of MaxCyte at 4.094 subject to Rule 16b-3 | ||
Thomas Ross over a year ago Exercise or conversion by Thomas Ross of 2607 shares of MaxCyte subject to Rule 16b-3 |
Bausch Health Management Efficiency
The company has Return on Asset of 0.0415 % which means that on every $100 spent on assets, it made $0.0415 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (23.0454) %, meaning that it generated no profit with money invested by stockholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.61, whereas Return On Tangible Assets are projected to grow to (0.06). At present, Bausch Health's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 2.7 B, whereas Total Assets are forecasted to decline to about 14.9 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Scully | Zoetis Inc | 71 | |
| Frank DAmelio | Zoetis Inc | 63 | |
| William Steere | Zoetis Inc | 83 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Michael Barber | Catalent | 60 | |
| John Greisch | Catalent | 65 | |
| Peter Zippelius | Catalent | 41 | |
| Jack Stahl | Catalent | 67 | |
| Rosemary Crane | Catalent | 60 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| JeanLuc Butel | Takeda Pharmaceutical Co | 64 | |
| Rolf Classon | Catalent | 75 | |
| JeanMichel Halfon | Teva Pharma Industries | 68 | |
| Nechemia Peres | Teva Pharma Industries | 61 | |
| Gregory Lucier | Catalent | 56 | |
| Michel Orsinger | Takeda Pharmaceutical Co | 62 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Roberto Mignone | Teva Pharma Industries | 48 | |
| Madhavan Balachandran | Catalent | 69 | |
| Shiro Kuniya | Takeda Pharmaceutical Co | 63 | |
| Antoinette Leatherberry | Zoetis Inc | 58 | |
Management Performance
| Return On Equity | -23.05 | ||||
| Return On Asset | 0.0415 |
Bausch Health Companies Leadership Team
Elected by the shareholders, the Bausch Health's board of directors comprises two types of representatives: Bausch Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bausch. The board's role is to monitor Bausch Health's management team and ensure that shareholders' interests are well served. Bausch Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bausch Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| D Hale, Independent Director | ||
| Jeff Hartness, Commercial Access | ||
| John Barresi, Controller, VP | ||
| Garen Sarafian, VP Relations | ||
| Sarah Kavanagh, Independent Director | ||
| Arthur Shannon, IR Contact Officer | ||
| Tage MD, Chief RD | ||
| William Humphries, Executive Vice President Company Group Chairman, Dermatology | ||
| Robert Butz, VP Affairs | ||
| Paul Herendeen, Chief Financial Officer, Executive Vice President | ||
| Brett Icahn, Independent Director | ||
| Richard Schutter, Independent Director | ||
| Seana Carson, Executive Counsel | ||
| Josh Coyle, Senior Salix | ||
| Amy Wechsler, Independent Director | ||
| Graham Jackson, Senior Officer | ||
| Sam Will, Senior Vice President - Finance, Chief Accounting Officer, Controller | ||
| Robert Power, Independent Director | ||
| Thomas Vadaketh, Ex CFO | ||
| Argeris Karabelas, Independent Director | ||
| Kathleen Fitzpatrick, Executive Officer | ||
| Joseph Gordon, President and Co-Head Bausch + Lomb/International | ||
| Jiny MBA, Senior Medical | ||
| Christina Ackermann, Executive Vice President, General Counsel and Head of Commercial Operations | ||
| William Woodfield, Senior Treasurer | ||
| Thomas Ross, Lead Independent Director | ||
| Donald Pearl, Senior Dermatologics | ||
| JeanJacques Charhon, Chief Officer | ||
| Andrew Eschenbach, Independent Director | ||
| Mirza Dautbegovic, Executive COO | ||
| Joseph Papa, Chairman of the Board, Chief Executive Officer | ||
| Aimee Lenar, Executive Pharma | ||
| John Paulson, Independent Director | ||
| Steven Miller, Independent Director | ||
| Thomas Appio, Executive Vice President Company Group Chairman, International | ||
| Robert Spurr, President - Salix | ||
| Cees Heiman, Senior Canada | ||
| Russel Robertson, Independent Director |
Bausch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bausch Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -23.05 | ||||
| Return On Asset | 0.0415 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 23.73 B | ||||
| Shares Outstanding | 367.8 M | ||||
| Shares Owned By Insiders | 11.08 % | ||||
| Shares Owned By Institutions | 71.40 % | ||||
| Number Of Shares Shorted | 11.65 M | ||||
| Price To Earning | 9.26 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bausch Health Companies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bausch Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bausch Health Companies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bausch Health Companies Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share (0.48) | Revenue Per Share 25.794 | Quarterly Revenue Growth 0.122 | Return On Assets 0.0415 |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.